Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancer Chemotherapy and Pharmacology|March 3, 2012
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumorsHajime Asahina, Yosuke Tamura, Hiroshi Nokihara, et al.
Gynecologic Oncology Reports|December 6, 2023
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinomaYuki Kojima, Hiroshi Yoshida, Toshihiro Okuya, et al.
Breast Cancer Research and Treatment|November 17, 2022
Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapyShu Yazaki, Tatsunori Shimoi, Masayuki Yoshida, et al.
BMC Bioinformatics|January 30, 2020
Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approachesArran K Turnbull, Cigdem Selli, Carlos Martinez-Perez, et al.
Plos One|May 15, 2013
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancerIssei Kurahashi, Yoshihiko Fujita, Tokuzo Arao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CancerMaki Tanioka, Cheng Fan, Joel S Parker, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
Nature Communications|March 29, 2017
Proteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-Lin Huang, Shunqiang Li, Philipp Mertins, et al.
Pageof 5